Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
NCT ID: NCT00265551
Last Updated: 2007-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2006-01-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SCA-136 (200 mg)
SCA-136 (400 mg)
olanzapine (15 mg)
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to remain hospitalized for at least first 4 weeks of study
* Needs hospitalization due to worsening of schizophrenia
Exclusion Criteria
* Previous use of clozapine
* Serious medical illness other than schizophrenia
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Little Rock, Arkansas, United States
Cerritos, California, United States
Costa Mesa, California, United States
La Mesa, California, United States
Oceanside, California, United States
Paramount, California, United States
Pico Rivera, California, United States
Rosemead, California, United States
San Diego, California, United States
San Diego, California, United States
Torrance, California, United States
Middletown, Connecticut, United States
Washington D.C., District of Columbia, United States
Fort Lauderdale, Florida, United States
Kissimmee, Florida, United States
North Miami, Florida, United States
Hoffman Estates, Illinois, United States
Indianapolis, Indiana, United States
Lake Charles, Louisiana, United States
Baltimore, Maryland, United States
Rockville, Maryland, United States
St Louis, Missouri, United States
Willingboro, New Jersey, United States
Cedarhurst, New York, United States
Holliswood, New York, United States
Chagrin Falls, Ohio, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Fort Washington, Pennsylvania, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Austin, Texas, United States
DeSoto, Texas, United States
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014 Jun;53:14-22. doi: 10.1016/j.jpsychires.2014.02.012. Epub 2014 Feb 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3153A1-202
Identifier Type: -
Identifier Source: org_study_id